Cellectar Biosciences Inc
CLRB
View Detailed Chart
3.040USD
+0.220+7.80%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
9.70MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+7.80%
5 Days
-5.59%
1 Month
-5.59%
6 Months
-36.40%
Year to Date
+3.05%
1 Year
-63.29%
View Detailed Chart
TradingKey Stock Score of Cellectar Biosciences Inc
Currency: USD Updated: 2026-02-06Key Insights
Cellectar Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 99 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 47.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cellectar Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cellectar Biosciences Inc Highlights
StrengthsRisks
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -0.38, at a low 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 89.12K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.95.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
47.000
Target Price
+1566.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Cellectar Biosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cellectar Biosciences Inc Info
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Ticker SymbolCLRB
CompanyCellectar Biosciences Inc
CEOCaruso (James V)
Websitehttps://www.cellectar.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68589.580
-1380.550 (-1.97%)
282.580
+22.390 (+8.61%)
2023.740
-27.990 (-1.36%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
